Yu, Yong <br/><br/>
Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.  [electronic resource] 

 -  Theranostics  2019 
 - 761-777 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1838-7640 
<br/><br/><label>Standard No.: </label>10.7150/thno.29520  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibiotics, Antineoplastic--administration & dosage<br/>Apoptosis--drug effects<br/>Cancer Survivors<br/>Cell Line, Tumor<br/>Cellular Senescence--drug effects<br/>DNA Methylation<br/>DNA, Neoplasm--metabolism<br/>Doxorubicin--administration & dosage<br/>Drug Delivery Systems<br/>Enhancer of Zeste Homolog 2 Protein--antagonists & inhibitors<br/>Epigenesis, Genetic<br/>Female<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Humans<br/>Indazoles--pharmacology<br/>Mice<br/>Mice, Nude<br/>Mixed Function Oxygenases--antagonists & inhibitors<br/>Proto-Oncogene Proteins--antagonists & inhibitors<br/>Pyridones--pharmacology<br/>Triple Negative Breast Neoplasms--genetics<br/>Xenograft Model Antitumor Assays